Stocks · News reference
Precipio (NASDAQ:PRPO) reported quarterly losses of $(0.12) per share. This is a 340 percent decrease over earnings of $0.05 per share from the same period last year. The company reported $7.021 million in sales this
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will host its Q3-2026 shareholder update call on November 10th, 2026. CEO Ilan Danieli highlighted continued revenue growth with the Products Division reaching an important milestone. The call will include company remarks and a moderated live Q&A session, with management providing insights into performance, strategy, and 2027 outlook.
Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.
Precipio (NASDAQ:PRPO) held its second-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Filed: 2026-08-14 AccNo: 0001104659-26-097364 Size: 227 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits